Alexander Zehnder, CureVac CEO (Bernd Wei'brod/picture-alliance/dpa/AP Images)
CureVac to cut costs, starts GSK-partnered bird flu vaccine trial
CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.
It said Wednesday that it enacted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
